Provided by Tiger Trade Technology Pte. Ltd.

Tyra Biosciences, Inc.

20.07
+0.10000.50%
Volume:411.67K
Turnover:8.35M
Market Cap:1.38B
PE:-8.35
High:20.59
Open:19.93
Low:19.73
Close:19.97
52wk High:40.65
52wk Low:13.29
Shares:68.76M
Float Shares:40.01M
Volume Ratio:0.57
T/O Rate:1.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4031
EPS(LYR):-2.0125
ROE:-45.31%
ROA:-28.46%
PB:3.90
PE(LYR):-9.97

Loading ...

Tyra Biosciences Price Target Cut to $40.00/Share from $50.00 by Oppenheimer

Dow Jones
·
Sep 23

Tyra Biosciences price target lowered to $40 from $50 at Oppenheimer

TIPRANKS
·
Sep 22

Tyra Biosciences, Inc. : H.c. Wainwright Cuts Target Price to $29 from $30

THOMSON REUTERS
·
Sep 22

Tyra Bioscience announces $400M equity financing offering

TIPRANKS
·
Sep 15

Stock Market Today: S&P 500, Dow and Nasdaq Futures Face Pressure as Brent Nears $108 and FOMC Commences Two-Day Meet— MSTR, CRWD, BMM in Focus

Benzinga Earnings
·
Sep 15

Tyra Biosciences Shares up 4.4% Premarket After $400 Mln Equity Raise

THOMSON REUTERS
·
Sep 14

Tyra Biosciences Rises After $400 Mln Equity Raise

Reuters
·
Sep 14

Tyra Biosciences Prices USD 400 Million Stock, Pre-Funded Warrant Offering at USD 22.03 Per Share

Reuters
·
Sep 14

Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

THOMSON REUTERS
·
Sep 14

Tyra Biosciences, - Announces Pricing of 9,079,000 Common Shares at $22.03 Per Share

THOMSON REUTERS
·
Sep 14

Tyra Biosciences Inc Files for Mixed Shelf; Size not Disclosed - SEC Filing

THOMSON REUTERS
·
Sep 14

Tyra Bioscience Director Makes Bold Insider Move That Could Signal Big Things Ahead

TIPRANKS
·
Sep 12

Tyra Biosciences Director Rehan Verjee Buys $20,000 of Common Shares

Reuters
·
Sep 12

Tyra Biosciences Price Target Maintained with a $53.00/Share by Wedbush

Dow Jones
·
Sep 10

Tyra Biosciences price target lowered to $30 from $45 at H.C. Wainwright

TIPRANKS
·
Sep 10

U.S. Stocks on the MOVE-Apple, Omnicom, Jersey Mike's Subs

Reuters
·
Sep 10

Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress

Dow Jones
·
Sep 09

Tyra Biosciences Shares Sink After Bladder-Cancer Treatment Causes Adverse Events in Some Patients During Clinical Trial

Dow Jones
·
Sep 09

U.S. Stocks on the MOVE-UGI, Chewy, Cognyte Software

Reuters
·
Sep 09

Tyra Biosciences Tumbles After Cancer Drug Misses Wall Street Expectations

Reuters
·
Sep 09